Tvardi Therapeutics, Inc. (TVRD) · INSIDERData sourcesSEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago
Public companyTvardi Therapeutics, Inc.
TVRDCIK 0001346830
Price$1.18
1 year-72.2%
Disclosed transactions9
Buys / sells0 / 0
Max Insider Score9
Connections with evidence6
TVRD · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 9 | SDShiff Susan Ph.D.Director | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 6,000 sh | Jun 9, 2026 | Jun 11, 2026 |
| 9 | KDKauh John Saewook M.D.Chief Medical Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 45.0K sh | Jan 29, 2026 | Feb 2, 2026 traded Jan 29, 2026 | +4d | SEC Form 4 | |
| 9 | OPO'Brien Stephen PaulPrincipal Accounting Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 15.0K sh | Jan 29, 2026 | Feb 2, 2026 traded Jan 29, 2026 | +4d | SEC Form 4 | |
| 9 | ANAlibhai Imran NizamudinDirector, Chief Executive Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 115.0K sh | Jan 29, 2026 | Feb 2, 2026 traded Jan 29, 2026 | +4d | SEC Form 4 | |
| 9 | CDConn Avi DanielChief Financial Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 45.0K sh | Jan 29, 2026 | Feb 2, 2026 traded Jan 29, 2026 | +4d | SEC Form 4 | |
| 9 | CDConn Avi DanielChief Financial Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 17.5K sh | Dec 16, 2025 | Dec 18, 2025 traded Dec 16, 2025 | +2d | SEC Form 4 | |
| 9 | KDKauh John Saewook M.D.Chief Medical Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 17.5K sh | Dec 16, 2025 | Dec 18, 2025 traded Dec 16, 2025 | +2d | SEC Form 4 | |
| 9 | OPO'Brien Stephen PaulPrincipal Accounting Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 4,000 sh | Dec 16, 2025 | Dec 18, 2025 traded Dec 16, 2025 | +2d | SEC Form 4 | |
| 9 | ANAlibhai Imran NizamudinDirector, Chief Executive Officer | TVRDTvardi Therapeutics, Inc. Grant or award | A | — 47.5K sh | Dec 16, 2025 | Dec 18, 2025 traded Dec 16, 2025 | +2d | SEC Form 4 | |
Director, Chief Executive Officer · Dec 18, 2025